开发用于治疗传染病的蛋白质-蛋白质相互作用抑制剂。
Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases.
机构信息
University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
出版信息
Adv Protein Chem Struct Biol. 2018;111:197-222. doi: 10.1016/bs.apcsb.2017.07.005. Epub 2017 Aug 24.
Abstract
Protein-protein interaction (PPI) inhibitors are a rapidly expanding class of therapeutics. Recent advances in our understanding of PPIs and success of early examples of PPI inhibitors demonstrate the feasibility of targeting PPIs. This review summarizes the techniques used for the discovery and optimization of a diverse set PPI inhibitors, focusing on the development of PPI inhibitors as new antibacterial and antiviral agents. We close with a summary of the advances responsible for making PPI inhibitors realistic targets for therapeutic intervention and brief outlook of the field.
摘要
蛋白质-蛋白质相互作用（PPI）抑制剂是一类快速发展的治疗药物。我们对 PPI 的理解的最新进展和早期 PPI 抑制剂的成功范例证明了靶向 PPI 的可行性。本综述总结了用于发现和优化多种 PPI 抑制剂的技术，重点是将 PPI 抑制剂开发为新型抗菌和抗病毒药物。最后，我们总结了使 PPI 抑制剂成为治疗干预的现实目标的进展，并简要展望了该领域的前景。
相似文献
1
Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases.开发用于治疗传染病的蛋白质-蛋白质相互作用抑制剂。
Adv Protein Chem Struct Biol. 2018;111:197-222. doi: 10.1016/bs.apcsb.2017.07.005. Epub 2017 Aug 24.
2
Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery.靶向蛋白-蛋白相互作用：抗 HIV 药物研发的一个有前途的途径。
Curr Med Chem. 2010;17(29):3393-409. doi: 10.2174/092986710793176357.
3
[Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].[新型抗HIV-1药物及候选药物的进展：2005 - 2008年]
Yao Xue Xue Bao. 2010 Feb;45(2):154-64.
4
EDITORIAL: New Avenues in Controlling Infectious Diseases.社论：控制传染病的新途径
Curr Top Med Chem. 2017;17(19):2113. doi: 10.2174/156802661719170616164549.
5
Structure Based Drug Design: Clinically Relevant HIV-1 Integrase Inhibitors.基于结构的药物设计：具有临床相关性的 HIV-1 整合酶抑制剂。
Curr Top Med Chem. 2018;18(31):2664-2680. doi: 10.2174/1568026619666190119143239.
6
Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.HIV-1整合酶的萘并恶唑嗪抑制剂：合成与生物学评价。
ChemMedChem. 2008 Jun;3(6):986-90. doi: 10.1002/cmdc.200800026.
7
Discovery and analysis of inhibitors of the human immunodeficiency integrase.人类免疫缺陷病毒整合酶抑制剂的发现与分析
Drug Des Discov. 1997 May;15(1):17-24.
8
Biologically-validated HIV integrase inhibitors with nucleobase scaffolds: structure, synthesis, chemical biology, molecular modeling, and antiviral activity.
Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):665-8. doi: 10.1080/15257770701490563.
9
Antiviral research--21st international conference.抗病毒研究——第21届国际会议
IDrugs. 2008 Jun;11(6):401-4.
10
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.吡咯芳基和吡咯杂芳基：HIV融合/附着、逆转录酶和整合酶的抑制剂。
Bioorg Med Chem. 2015 Sep 1;23(17):5247-63. doi: 10.1016/j.bmc.2015.06.016. Epub 2015 Jun 14.
引用本文的文献
1
Hot-Spot-Guided Generative Deep Learning for Drug-Like PPI Inhibitor Design.用于类药物蛋白质-蛋白质相互作用抑制剂设计的热点引导生成式深度学习
Interdiscip Sci. 2025 Sep 2. doi: 10.1007/s12539-025-00756-w.
2
Polymers for Disrupting Protein-Protein Interactions: Where Are We and Where Should We Be?聚合物类药物干扰蛋白-蛋白相互作用：路在何方？
Biomacromolecules. 2024 Oct 14;25(10):6229-6249. doi: 10.1021/acs.biomac.4c00850. Epub 2024 Sep 10.
3
Rational design of small-sized peptidomimetic inhibitors disrupting protein-protein interaction.破坏蛋白质-蛋白质相互作用的小型拟肽抑制剂的合理设计。
RSC Med Chem. 2024 May 7;15(7):2212-2225. doi: 10.1039/d4md00202d. eCollection 2024 Jul 17.
4
Molecular Determinants of Human Rhinovirus Infection, Assembly, and Conformational Stability at Capsid Protein Interfaces.人鼻病毒感染、组装和衣壳蛋白界面构象稳定性的分子决定因素。
J Virol. 2022 Dec 14;96(23):e0084022. doi: 10.1128/jvi.00840-22. Epub 2022 Nov 14.
5
Design and Synthesis of Hepatitis B Virus (HBV) Capsid Assembly Modulators and Evaluation of Their Activity in Mammalian Cell Model.乙型肝炎病毒（HBV）衣壳组装调节剂的设计与合成及其在哺乳动物细胞模型中的活性评估
Pharmaceuticals (Basel). 2022 Jun 22;15(7):773. doi: 10.3390/ph15070773.
6
Protein-Protein Binding Free Energy Predictions with the MM/PBSA Approach Complemented with the Gaussian-Based Method for Entropy Estimation.采用基于高斯熵估计方法补充的MM/PBSA方法预测蛋白质-蛋白质结合自由能
ACS Omega. 2022 Mar 22;7(13):11057-11067. doi: 10.1021/acsomega.1c07037. eCollection 2022 Apr 5.
7
Inhibiting Type VI Secretion System Activity with a Biomimetic Peptide Designed To Target the Baseplate Wedge Complex.用设计用于靶向基板楔形复合物的仿生肽抑制 VI 型分泌系统活性。
mBio. 2021 Aug 31;12(4):e0134821. doi: 10.1128/mBio.01348-21. Epub 2021 Aug 10.
8
Structural Profiling of Bacterial Effectors Reveals Enrichment of Host-Interacting Domains and Motifs.细菌效应蛋白的结构分析揭示了宿主相互作用结构域和基序的富集。
Front Mol Biosci. 2021 May 3;8:626600. doi: 10.3389/fmolb.2021.626600. eCollection 2021.
9
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.推进小分子SARS-CoV-2发现的资源与计算策略：从大流行中吸取的教训及为未来健康危机做准备
Comput Struct Biotechnol J. 2021;19:2537-2548. doi: 10.1016/j.csbj.2021.04.059. Epub 2021 Apr 26.
10
Scanning Protein Surfaces with DNA-Encoded Libraries.用 DNA 编码文库扫描蛋白质表面。
ChemMedChem. 2021 Apr 8;16(7):1048-1062. doi: 10.1002/cmdc.202000869. Epub 2020 Dec 28.
本文引用的文献
1
A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail.五国发出全球合作开展抗生素管理的呼吁：团结则成，分裂则败。
Lancet Infect Dis. 2017 Feb;17(2):e56-e63. doi: 10.1016/S1473-3099(16)30386-3. Epub 2016 Nov 18.
2
Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation: DRUGGABILITY OF THE SMALL GTPase Rab27a.中性粒细胞胞吐作用抑制剂（Nexinhibs）的鉴定，中性粒细胞胞吐作用和炎症的小分子抑制剂：小GTP酶Rab27a的成药潜力
J Biol Chem. 2016 Dec 9;291(50):25965-25982. doi: 10.1074/jbc.M116.741884. Epub 2016 Oct 4.
3
Redefining the roles of the FtsZ-ring in bacterial cytokinesis.重新定义FtsZ环在细菌胞质分裂中的作用。
Curr Opin Microbiol. 2016 Dec;34:90-96. doi: 10.1016/j.mib.2016.08.008. Epub 2016 Sep 10.
4
Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.调整基于吡啶的非共价抑制剂的效力和药代动力学性质。
ACS Med Chem Lett. 2016 Jun 9;7(8):797-801. doi: 10.1021/acsmedchemlett.6b00194. eCollection 2016 Aug 11.
5
Imbalance in chemical space: How to facilitate the identification of protein-protein interaction inhibitors.化学空间的失衡：如何促进蛋白质-蛋白质相互作用抑制剂的识别
Sci Rep. 2016 Apr 1;6:23815. doi: 10.1038/srep23815.
6
2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein-protein interactions.2P2Idb v2：一个致力于蛋白质-蛋白质相互作用正构调节的结构数据库的更新
Database (Oxford). 2016 Mar 15;2016. doi: 10.1093/database/baw007. Print 2016.
7
2015 Update of the Drug Resistance Mutations in HIV-1.《2015年HIV-1耐药性突变更新》
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
8
Why Do We Need New Drug Classes for HIV Treatment and Prevention?为什么我们需要用于治疗和预防艾滋病的新型药物类别？
Curr Top Med Chem. 2016;16(12):1343-9. doi: 10.2174/1568026616999151013124606.
9
The emerging threat of multidrug-resistant Gram-negative bacteria in urology.泌尿外科学中出现的多重耐药革兰氏阴性菌的新威胁。
Nat Rev Urol. 2015 Oct;12(10):570-84. doi: 10.1038/nrurol.2015.199. Epub 2015 Sep 1.
10
State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.靶向小分子抑制剂的蛋白质-蛋白质相互作用的最新策略。
Chem Soc Rev. 2015 Nov 21;44(22):8238-59. doi: 10.1039/c5cs00252d. Epub 2015 Aug 6.
Zotero 插件